Please assess the completion status of the following clinical trial:

Trial Title: Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Is at least 25 years old at Visit 1 (Screening).~2. Is male, or is female and meets all of the following criteria:~   1. Not breastfeeding~  2. Negative pregnancy test result at Visit 1 (not applicable to post-menopausal or surgically sterile females)~  3. Surgically sterile, postmenopausal, or if of childbearing potential, must practice and be willing to continue to practice appropriate birth control during the entire duration of the study.~3. Body mass index (BMI) 20.0 to 45.0 kg/m² (inclusive) at Visit 1 (Screening).~4. Has a physical examination with no clinically significant abnormalities as judged by the investigator.~5. Has T2DM and an HbA1c of 7.5% to 10.5%, inclusive, at Visit 1.~6. Has an estimated glomerular filtration rate (eGFR) value of ≥60 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation.~7. Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 3 months prior to Visit 1:~   1. Thiazolidinedione, sulfonylurea, dipeptidyl peptidase-4 inhibitors, and alpha-glucosidase inhibitors~  2. Hormone replacement therapy (female subjects) and testosterone (male subjects)~  3. Oral contraceptives (female subjects)~  4. Antihypertensive agents~  5. Lipid-lowering agents~  6. Thyroid replacement therapy~  7. Antidepressant agents~8. Ability to understand and willingness to adhere to protocol requirements.~Exclusion Criteria:~1. Has a clinically significant medical condition as judged by the investigator that could potentially affect study participation and/or personal well-being, including but not limited to the following conditions:~   1. Hepatic disease~  2. Gastrointestinal disease~  3. Endocrine disorder (T2DM is allowed)~  4. Cardiovascular disease~  5. Central nervous system diseases~  6. Psychiatric or neurological disorders~  7. Organ transplantation~  8. Chronic or acute infection~  9. Orthostatic hypotension, fainting spells or blackouts~  10. Allergy or hypersensitivity.~2. A history of diabetic ketoacidosis or hyperosmolar non-ketotic hyperglycemia within the past year.~3. Prior major surgery of any kind within 6 months of Visit 1.~4. A history of \>3% weight change within 3 months of Visit 1.~5. A clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormality, other than that related to T2DM, judged by the investigator to be clinically significant at Visit 1.~6. An alanine aminotransferase or aspartate aminotransferase result \>2.5 × upper limit of normal (ULN) or a bilirubin result \>1.5 × ULN.~7. A physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study.~8. Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following excluded medications:~   1. Metformin within 2 months of Visit 1 (Screening)~  2. Insulin within 2 weeks of Visit 1 (Screening) or for more than 1 week within 3 months of Visit 1 (Screening)~  3. Glucagon-like peptide-1 receptor agonists or sodium-glucose co-transporter 2 inhibitors within 3 months of Visit 1~  4. Drugs known to affect body weight, including prescription medications and over-the-counter anti obesity agents within 3 months of Visit 1.~  5. Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption within 3 months of Visit 1~  6. Planned use of any drug treatment that affects gastric pH (prescription or over-the-counter), such as H2-receptor antagonists and proton pump inhibitors, after Visit 2 (Week -2), or planned chronic use of any antacids (i.e., more than twice per week) after Visit 2 (Week -2)~  7. Cationic drugs that are eliminated by renal tubular secretion within 1 week of Visit 1.~  8. Iodinated contrast dye within 1 week prior to Visit 1.~  9. Investigational drug within 2 months (or five half-lives of the investigational drug, whichever is greater) of the date of the first dose of randomized study medication.~  10. Met DR or double-blind matching placebo for Met DR at any time prior to Visit 1 (Screening)~9. Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures.~10. Had a blood transfusion or experienced significant blood loss (i.e., \>500 mL), including loss due to blood donation, within 2 months prior to Visit 1 (Screening), or is planning to donate blood during the study.~11. Has known immune system based allergies or hypersensitivity to any component of study treatment. A history of gastrointestinal intolerance to metformin is not exclusionary.~12. Is employed by Elcelyx Therapeutics, Inc. (that is an employee, contract worker, or designee of the company).~13. Has a fasting plasma glucose value \>270 mg/dL at Visit 1 (Screening), Visit 2 (Week -2), and an unscheduled visit to be completed within 1 week following Visit 2. The unscheduled visit is to be completed only for subjects with a fasting plasma glucose value \>270 mg/dL at Visit 1 and Visit 2.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 600 mg Met DR qAM (Type: EXPERIMENTAL): 600 mg metformin delayed-release once daily in the morning
- 900 mg Met DR qAM (Type: EXPERIMENTAL): 900 mg metformin delayed-release once daily in the morning
- 1200 mg Met DR qAM (Type: EXPERIMENTAL): 1200 mg metformin delayed-release once daily in the morning
- 1500 mg Met DR qAM (Type: EXPERIMENTAL): 1500 mg metformin delayed-release once daily in the morning
- Placebo-1 (Type: PLACEBO_COMPARATOR): placebo match for 600 and 1200 mg Met DR qAM treatment groups
- Placebo-2 (Type: PLACEBO_COMPARATOR): placebo match for 900 and 1500 mg Met DR qAM treatment groups
- 2000 mg Met IR (Type: ACTIVE_COMPARATOR): 1000 mg metformin immediate-release twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).